BioVersys AG Income Statement

Financials in millions CHF. Fiscal year is January - December.

Millions CHF. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Operating Revenue	0.8	-	-
Other Revenue	2.38	1.21	1.14
Revenue	3.18	1.21	1.14
Revenue Growth (YoY)	161.75%	6.50%	-
Gross Profit	3.18	1.21	1.14
Selling, General & Admin	6.73	6.99	4.02
Research & Development	16.5	12.95	14.83
Other Operating Expenses	-0.09	-	-
Operating Expenses	23.14	19.94	18.84
Operating Income	-19.96	-18.72	-17.7
Interest Expense	-1.08	-1.04	-0.7
Interest & Investment Income	0.05	0.5	0.48
Currency Exchange Gain (Loss)	-0.01	0.13	-0.16
Other Non Operating Income (Expenses)	-0.81	0.42	-0.22
Pretax Income	-21.81	-18.72	-18.3
Income Tax Expense	0.02	-	-
Net Income	-21.83	-18.72	-18.3
Net Income to Common	-21.83	-18.72	-18.3
Shares Outstanding (Basic)	6	3	3
Shares Outstanding (Diluted)	6	3	3
Shares Change (YoY)	68.49%	11.60%	-
EPS (Basic)	-3.89	-5.62	-6.13
EPS (Diluted)	-3.89	-5.62	-6.13
Free Cash Flow	-22.16	-15.61	-11.7
Free Cash Flow Per Share	-3.95	-4.68	-3.92
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-628.76%	-1543.45%	-1554.17%
Profit Margin	-687.56%	-1543.20%	-1606.76%
Free Cash Flow Margin	-698.02%	-1287.06%	-1027.57%
EBITDA	-19.89	-18.66	-17.65
D&A For EBITDA	0.07	0.06	0.06
EBIT	-19.96	-18.72	-17.7
Revenue as Reported	3.27	1.21	1.14

Source: S&P Global Market Intelligence. Standard template. Financial Sources.